Literature DB >> 19747144

Potential targets and their relevant inhibitors in anti-influenza fields.

Jianzhi Gong1, Hao Fang, Minyong Li, Yu Liu, Kanghui Yang, Yingzi Liu, Wenfang Xu.   

Abstract

Influenza is a disease for deeply affecting millions of people every year. Recently, there has been considerable concern regarding the highly pathogenic H5N1 avian influenza virus, and its human pandemic potential. With developments in viral biology, there are more novel antiviral strategies targeting these viruses. In this review, we will discuss several proven and potential anti-influenza targets, including viral factors (such as hemagglutinin (HA), M2 ion channel protein, RNA-dependent RNA polymerase (RdRp), nucleoprotein (NP), non-structural protein (NS) and neuraminidase (NA)) and host factors (such as v-ATPase, protease, inosine monophosphate dehydrogenase (IMPDH) and intracellular signalling cascades), and their relevant inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19747144     DOI: 10.2174/092986709789104984

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  14 in total

1.  High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity.

Authors:  Ching-Yao Su; Ting-Jen R Cheng; Meng-I Lin; Shi-Yun Wang; Wen-I Huang; Shao-Ying Lin-Chu; Yu-Hou Chen; Chung-Yi Wu; Michael M C Lai; Wei-Chieh Cheng; Ying-Ta Wu; Ming-Daw Tsai; Yih-Shyun E Cheng; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

2.  Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.

Authors:  Randal A Byrn; Steven M Jones; Hamilton B Bennett; Chris Bral; Michael P Clark; Marc D Jacobs; Ann D Kwong; Mark W Ledeboer; Joshua R Leeman; Colleen F McNeil; Mark A Murcko; Azin Nezami; Emanuele Perola; Rene Rijnbrand; Kumkum Saxena; Alice W Tsai; Yi Zhou; Paul S Charifson
Journal:  Antimicrob Agents Chemother       Date:  2014-12-29       Impact factor: 5.191

3.  Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans.

Authors:  Julia Koch-Heier; Annika Schönsiegel; Lara Maria Waidele; Julian Volk; Yvonne Füll; Christian Wallasch; Sebastian Canisius; Michael Burnet; Oliver Planz
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

4.  Proteomic analysis of the mice hippocampus after preconditioning induced by N-methyl-D-aspartate (NMDA).

Authors:  Gabrielle do Amaral e Silva Müller; Samuel Vandresen-Filho; Carolina Pereira Tavares; Angela C O Menegatti; Hernán Terenzi; Carla Inês Tasca; Patricia Cardoso Severino
Journal:  J Mol Neurosci       Date:  2012-09-22       Impact factor: 3.444

5.  Structural analysis of specific metal chelating inhibitor binding to the endonuclease domain of influenza pH1N1 (2009) polymerase.

Authors:  Eva Kowalinski; Chloe Zubieta; Andrea Wolkerstorfer; Oliver H J Szolar; Rob W H Ruigrok; Stephen Cusack
Journal:  PLoS Pathog       Date:  2012-08-02       Impact factor: 6.823

6.  Anti-influenza virus effect of aqueous extracts from dandelion.

Authors:  Wen He; Huamin Han; Wei Wang; Bin Gao
Journal:  Virol J       Date:  2011-12-14       Impact factor: 4.099

Review 7.  Using the Hepatitis C Virus RNA-Dependent RNA Polymerase as a Model to Understand Viral Polymerase Structure, Function and Dynamics.

Authors:  Ester Sesmero; Ian F Thorpe
Journal:  Viruses       Date:  2015-07-17       Impact factor: 5.048

8.  Integrating computational modeling and functional assays to decipher the structure-function relationship of influenza virus PB1 protein.

Authors:  Chunfeng Li; Aiping Wu; Yousong Peng; Jingfeng Wang; Yang Guo; Zhigao Chen; Hong Zhang; Yongqiang Wang; Jiuhong Dong; Lulan Wang; F Xiao-Feng Qin; Genhong Cheng; Tao Deng; Taijiao Jiang
Journal:  Sci Rep       Date:  2014-11-26       Impact factor: 4.379

9.  Using mutagenesis to explore conserved residues in the RNA-binding groove of influenza A virus nucleoprotein for antiviral drug development.

Authors:  Chia-Lin Liu; Hui-Chen Hung; Shou-Chen Lo; Ching-Hui Chiang; I-Jung Chen; John T-A Hsu; Ming-Hon Hou
Journal:  Sci Rep       Date:  2016-02-26       Impact factor: 4.379

Review 10.  Progress of small molecular inhibitors in the development of anti-influenza virus agents.

Authors:  Xiaoai Wu; Xiuli Wu; Qizheng Sun; Chunhui Zhang; Shengyong Yang; Lin Li; Zhiyun Jia
Journal:  Theranostics       Date:  2017-02-08       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.